Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Interview: Sandoz CEO On Biosimilars And Reshaping US Business

Executive Summary

Observers were left surprised by the size of the decline in US sales at Sandoz during the fourth quarter. Richard Francis, CEO of Novartis' generics division, told Scrip about plans to turn the business around in which biosimilars will figure largely.

Advertisement

Related Content

Novartis Blows Storm Clouds Off Sandoz US In Aurobindo Sale
Novartis Blows Storm Clouds Off Sandoz US In Aurobindo Sale
Novartis Sees The Light And Plumps For Alcon Spin-Off
Novartis Sees The Light And Plumps For Alcon Spin-Off
What Will Novartis Do With $13bn Cash Pile From GSK?
Deal Watch: Sanofi Finds Ideal 'Partner' For Leukine
New Dawn At Novartis As Narasimhan Demands Breakthroughs

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100270

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel